

FIG. 1




FIG. 2




FIG. 3




FIG. 4





FIG. 5



# subjects						
Dose Cohort 1 Group A	7	6	6	6	5	5
Dose Cohort 2 Group A	7	7	7	6	6	6
Dose Cohort 3 Group A	6	6	6	6	6	6
Dose Cohort 1 Group B	6	6	6	6	6	5
Dose Cohort 2 Group B	7	7	7	7	7	7
Dose Cohort 3 Group B	9	6	6	5	5	5





FIG. 6

FIG. 7

Group A: ≥ 30 kg and ≤ 60 kg for patients enrolled in the dose-ranging portion and ≥ 30 kg for patients enrolled once dose is selected (second portion); Group B: ≥ 10 kg and < 30 kg



Abbreviations: PD= pharmacodynamics, PK= pharmacokinetic, qw= once a week, q2w= once every other week.

FIG. 8




FIG. 9A





FIG. 9B

◆ Dose cohort 1 Group A (2.0 mg/kg Q2W) ◆ Dose cohort 2 Group A (3.0 mg/kg Q2W) ◆ Dose cohort 3 Group A (2.0 mg/kg QW)
 ◆ Dose cohort 1 Group B (2.5 mg/kg Q2W) ◆ Dose cohort 2 Group B (4.0 mg/kg Q2W) ◆ Dose cohort 3 Group B (2.5 mg/kg QW)



Number of subjects	7	7	6	6	5	5	5
	6	6	6	6	6	6	6
	7	7	7	7	6	5	6
	7	7	7	7	7	6	6
	6	6	6	6	6	6	6
	6	6	6	6	5	5	5




FIG. 10A




FIG. 10B




FIG. 11A




FIG. 11B




FIG. 11C

